EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: A review of three Phase II studies



Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: A review of three Phase II studies



Clinical Therapeutics 25(1): 19-34, January



Background: Oral bisphosphonates are well established for the treatment and prevention of postmenopausal osteoporosis; however, they are poorly absorbed from the gastrointestinal (GI) tract and have been associated with GI adverse events. Thus, current dosing guidelines recommend that the patient not eat or lie down for at least 30 minutes after taking oral bisphosphonates, a requirement that is inconvenient and may be associated with reduced compliance. The drawbacks of these dosing requirements may be overcome either by reducing dosing frequency or by using alternative routes of administration. Objective: Ibandronate is a potent nitrogen-containing bisphosphonate that can be given orally or IV, daily or intermittently, with a between-dose interval of up to 3 months. This article presents the results of published Phase II trials of the efficacy and safety profile of oral and IV ibandronate administered daily or intermittently to postmenopausal women with low bone mass. Methods: MEDLINE was searched through January 2002 to identify all published Phase II clinical studies of oral and IV ibandronate in the treatment of postmenopausal osteoporosis. Results: In the 3 Phase II studies identified, marked reductions in biochemical markers of bone resorption (50%-70%) and bone formation (40%-50%) were seen to a similar and statistically significant extent with oral ibandronate 2.5 mg/d (P<0.001), oral ibandronate 20 mg QOD given for 12 doses at the start of each 3-monthly period (P<0.001), and injections of ibandronate 2 mg IV given every 3 months (P<0.01). All treatment regimens produced comparable significant increases in bone mineral density at the lumbar spine (P<0.01) and hip (P<0.05). Ibandronate was well tolerated when administered both orally and as an IV injection. Conclusions: In these Phase II studies, oral or IV ibandronate, administered continuously or intermittently, reduced markers of bone turnover, significantly increased bone mineral density, and was well tolerated in the treatment of osteoporosis in postmenopausal women. The data from these studies provided the rationale for further investigation of ibandronate in larger, longer-term Phase III studies evaluating its potential as an efficacious and flexible alternative to existing bisphosphonate regimens.

(PDF emailed within 0-6 h: $19.90)

Accession: 010520476

Download citation: RISBibTeXText

PMID: 12637110

DOI: 10.1016/s0149-2918(03)90005-1



Related references

Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone (New York) 30(1): 320-324, January, 2002

Bone histomorphometric evaluation of daily and intermittent oral ibandronate in postmenopausal osteoporosis. Calcified Tissue International 72(4): 402, April, 2003

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporosis International 15(3): 231-237, 2004

The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone (New York) 19(5): 527-533, 1996

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis International 15(10): 792-798, 2004

Effect of rectal salmon calcitonin treatment on bone mass and bone turnover in patients with established postmenopausal osteoporosis: A-year crossover study. Current Therapeutic Research 54(4): 458-465, 1993

Effect on bone mass and bone turnover of a 2-year intermittent or continuous treatment with salmon calcitonin nasal spray in postmenopausal osteoporotic patients. Cohn, D V, Gennari, C, Tashjian, A H, Jr International Congress Series; Calcium regulating hormones and bone metabolism: Basic and clinical aspects, Vol 11: 400-406, 1992

Daily oral ibandronate prevents bone loss in postmenopausal women without osteoporosis. Journal of Bone & Mineral Research 17(Suppl 1): S157, September, 2002

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. Journal of Bone and Mineral Research 19(1): 11-18, 2004

Daily or monthly ibandronate prevents or restores deteriorations of bone mass, architecture, biomechanical properties and markers of bone turnover in androgen-deficient aged rats. Aging Male 14(4): 220-230, 2012

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone 46(3): 660-665, 2010

Polymorphism of the gene for vitamin D receptor, bone mass, and bone turnover in women with postmenopausal osteoporosis. Revista Clinica Espanola 200(4): 198-202, 2000

Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis. Endokrynologia Polska 67(2): 174-184, 2016